John W. Rogers Jr.
Ariel Appreciation Fund
John W. Rogers Jr. Charles River Laboratories stake
total: 70
Ariel Appreciation Fund CRL trades
- Total transactions:
- 21
- New positions:
- 1
- Added:
- 9
- Reduced:
- 11
- Held since:
- 2019 Q3
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, John W. Rogers Jr. holds 171,201 Charles River Laboratories (CRL) shares with a market value of roughly $29.53M accounting for 3.38% of the overall portfolio. To date, the estimated cost basis is nearly $165.86 for "buy" trades and estimated average "sell" price is $195.06. Ariel Appreciation Fund first purchased CRL in 2019 Q3, initially acquiring 167,680 shares. Since the initial investment in Charles River Laboratories (CRL), Ariel Appreciation Fund has made 20 more transactions.
When did John W. Rogers Jr. buy Charles River Laboratories (CRL)?
John W. Rogers Jr. first invested in Charles River Laboratories (CRL) in 2019 Q3 at the reported quarter-end price of $132.37 per share.
What's the cost basis of Ariel Appreciation Fund's CRL stake?
The estimated cost basis for Charles River Laboratories (CRL) stake is around $165.86 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $165.86
- Weighted AVG sell price:
- $195.06
John W. Rogers Jr.'s historical trades in Charles River Laboratories
21 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
3.38%
|
171,201
|
$172.50
|
$29,532,172
|
-11.21% (-21,623)
|
-0.42%
|
|
2025 Q4
|
4.32%
|
192,824
|
$199.48
|
$38,464,532
|
+1.79% (+3,388)
|
+0.08%
|
|
2025 Q3
|
3.31%
|
189,436
|
$156.46
|
$29,639,157
|
+3.33% (+6,099)
|
+0.11%
|
|
2025 Q2
|
3.28%
|
183,337
|
$151.73
|
$27,817,723
|
+32.31% (+44,766)
|
+0.8%
|
|
2025 Q1
|
2.45%
|
138,571
|
$150.52
|
$20,857,707
|
-6.97% (-10,379)
|
-0.16%
|
|
2024 Q4
|
2.88%
|
148,950
|
$184.60
|
$27,496,170
|
+3.21% (+4,629)
|
+0.09%
|
|
2024 Q1
|
3.64%
|
144,321
|
$270.95
|
$39,103,775
|
-5.72% (-8,751)
|
-0.22%
|
|
2023 Q4
|
3.38%
|
153,072
|
$236.40
|
$36,186,221
|
-9.19% (-15,488)
|
-0.36%
|
|
2023 Q2
|
3.19%
|
168,560
|
$210.25
|
$35,439,740
|
+13.11% (+19,533)
|
+0.37%
|
|
2023 Q1
|
2.62%
|
149,027
|
$201.82
|
$30,076,629
|
+23.28% (+28,140)
|
+0.49%
|
|
2022 Q3
|
2.34%
|
$196.80
|
+8.98% (+9,964)
|
|||
|
2022 Q2
|
2.16%
|
$213.97
|
+105.35% (+56,907)
|
|||
|
2022 Q1
|
1.19%
|
$283.97
|
+22.66% (+9,979)
|
|||
|
2021 Q4
|
1.18%
|
$376.78
|
-7.23% (-3,431)
|
|||
|
2021 Q3
|
1.43%
|
$412.67
|
-19.52% (-11,512)
|
|||
|
2021 Q1
|
1.27%
|
$289.83
|
-8.10% (-5,200)
|
|||
|
2020 Q4
|
1.36%
|
$249.86
|
-20.45% (-16,500)
|
|||
|
2020 Q2
|
1.47%
|
$174.35
|
-20.02% (-20,200)
|
|||
|
2020 Q1
|
1.50%
|
$126.21
|
-37.91% (-61,600)
|
|||
|
2019 Q4
|
1.89%
|
$152.76
|
-3.10% (-5,200)
|
|||
|
2019 Q3
|
1.72%
|
$132.37
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.